title: University of Wisconsin solution versus Celsior solution in clinical pancreas transplantation.
abstract: BACKGROUND
  This study compared the safety and efficacy of University of Wisconsin solution (UW) and Celsior solution (C) in pancreas transplantation (PTx).
  
  
  METHODS
  A retrospective review of 154 PTx performed over a 61-month period included 77 grafts preserved with UW and 77 with C. The two groups were comparable for both donor and recipient characteristics.
  
  
  RESULTS
  After a mean cold ischemia time of 624 minutes (range 360 to 945 minutes) for UW versus 672 minutes (range 415 to 1005 minutes) for C (P = NS), no primary endocrine nonfunction occurred. Delayed endocrine function was diagnosed in two grafts in the UW group (2.6%) versus none in the C group (P = NS). After a minimum follow-up of 4 months (mean 26.5 +/- 15.2 months), 22 recipients (UW = 11 vs C = 11; P = NS) required relaparotomy. Overall, 18 pancreata were lost due to either patient death with functioning graft (UW = 4 vs C = 1; P = NS) or graft loss due to other reasons (UW = 8 vs C = 5; P = NS). Actuarial 1- and 5-year patient survival rates were 93.5% and 86.8% for UW compared with 98.7% and 98.7% for C (P = .04). Actuarial graft survival rates at the same times were 88.3% and 75.0% for UW compared with 90.4% and 90.4% for C (P = NS).
  
  
  CONCLUSIONS
  Within the range of cold ischemia times reported in this study, UW and C show similar safety and efficacy profiles for PTx.
authors.affiliation: Centro Regionale di Riferimento per la Cura delle Malattie del Pancreas, University of Pisa, Pisa, Italy.
authors.forename: U
authors.initials: U
authors.lastname: Boggi
authors.forename: S
authors.initials: S
authors.lastname: Signori
authors.forename: F
authors.initials: F
authors.lastname: Vistoli
authors.forename: M
authors.initials: M
authors.lastname: Del Chiaro
authors.forename: A
authors.initials: A
authors.lastname: Pietrabissa
authors.forename: C
authors.initials: C
authors.lastname: Croce
authors.forename: M
authors.initials: M
authors.lastname: Barsotti
authors.forename: T Vanadia
authors.initials: TV
authors.lastname: Bartolo
authors.forename: G
authors.initials: G
authors.lastname: Amorese
authors.forename: E
authors.initials: E
authors.lastname: Capocasale
authors.forename: R
authors.initials: R
authors.lastname: Della Valle
authors.forename: M P
authors.initials: MP
authors.lastname: Mazzoni
authors.forename: F
authors.initials: F
authors.lastname: Mosca
mesh_terms: D000241:Adenosine; D000328:Adult; D000493:Allopurinol; D001787:Blood Group Incompatibility; D002102:Cadaver; D002423:Cause of Death; D004187:Disaccharides; D004573:Electrolytes; D005260:Female; D005971:Glutamates; D005978:Glutathione; D006639:Histidine; D006801:Humans; D007328:Insulin; D007558:Italy; D008297:Male; D008353:Mannitol; D019188:Organ Preservation Solutions; D016035:Pancreas Transplantation / Q000706:statistics & numerical data*; D011183:Postoperative Complications; D011887:Raffinose; D012189:Retrospective Studies; D014019:Tissue Donors / Q000706:statistics & numerical data*; D017211:Treatment Failure
chemical_list: C088453:Celsior; D004187:Disaccharides; D004573:Electrolytes; D005971:Glutamates; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D006639:Histidine; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose